Dianthus Therapeutics (DNTH) Competitors $23.80 +0.76 (+3.30%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNTH vs. MOR, SWTX, ZLAB, VCEL, GMTX, KYMR, VERA, BHC, ARWR, and DYNShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), Vericel (VCEL), Gemini Therapeutics (GMTX), Kymera Therapeutics (KYMR), Vera Therapeutics (VERA), Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. MorphoSys SpringWorks Therapeutics Zai Lab Vericel Gemini Therapeutics Kymera Therapeutics Vera Therapeutics Bausch Health Companies Arrowhead Pharmaceuticals Dyne Therapeutics MorphoSys (NASDAQ:MOR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do insiders & institutionals believe in MOR or DNTH? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor MOR or DNTH? In the previous week, Dianthus Therapeutics had 5 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 2 mentions for MorphoSys. Dianthus Therapeutics' average media sentiment score of 0.69 beat MorphoSys' score of -0.27 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MOR or DNTH? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Do analysts prefer MOR or DNTH? MorphoSys presently has a consensus target price of $14.33, indicating a potential downside of 24.45%. Dianthus Therapeutics has a consensus target price of $46.43, indicating a potential upside of 95.08%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Is MOR or DNTH more profitable? MorphoSys has a net margin of -226.79% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Which has preferable earnings & valuation, MOR or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than MorphoSys. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Dianthus Therapeutics$5.37M131.27-$43.56M-$2.50-9.52 Does the MarketBeat Community favor MOR or DNTH? MorphoSys received 2 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Dianthus TherapeuticsOutperform Votes2395.83% Underperform Votes14.17% SummaryDianthus Therapeutics beats MorphoSys on 15 of the 19 factors compared between the two stocks. Ad Diversified Trading InstituteCombine the QQQ, IWM and SPY in one tradeIf you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…You can find out about this “2-Click Trade” here. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$681.92M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-9.5210.5991.3417.19Price / Sales131.27195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book2.095.104.794.78Net Income-$43.56M$151.51M$120.07M$225.60M7 Day Performance-0.04%-2.14%-1.90%-1.24%1 Month Performance17.41%-3.13%11.43%3.06%1 Year Performance172.00%11.51%30.59%16.50% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.3413 of 5 stars$23.80+3.3%$46.43+95.1%+213.2%$681.92M$5.37M-9.5280Analyst ForecastNews CoverageMORMorphoSys0.128 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageSWTXSpringWorks Therapeutics2.011 of 5 stars$37.91-1.0%$69.50+83.3%+11.3%$2.82B$5.45M-9.87305ZLABZai Lab1.7111 of 5 stars$25.94-1.5%$55.00+112.0%-7.4%$2.82B$355.75M-9.512,175VCELVericel1.4466 of 5 stars$56.98-0.9%$59.71+4.8%+66.0%$2.81B$226.84M957.83300Analyst ForecastGMTXGemini TherapeuticsN/A$64.89+1.0%N/A+10.4%$2.81BN/A-64.8930KYMRKymera Therapeutics2.266 of 5 stars$43.38+3.0%$53.88+24.2%+66.0%$2.81B$87.56M-18.00170Positive NewsVERAVera Therapeutics3.4798 of 5 stars$44.12+0.2%$59.22+34.2%+180.4%$2.79BN/A-16.8840Insider TradeBHCBausch Health Companies2.8466 of 5 stars$7.67-1.8%$7.75+1.0%+3.0%$2.77B$8.76B-16.2720,270Analyst RevisionARWRArrowhead Pharmaceuticals4.3641 of 5 stars$22.15+1.4%$42.70+92.8%-30.1%$2.76B$3.55M-4.35400Analyst ForecastInsider TradeDYNDyne Therapeutics3.1221 of 5 stars$26.00+1.0%$50.42+93.9%+104.9%$2.65BN/A-7.23100 Related Companies and Tools Related Companies MorphoSys Alternatives SpringWorks Therapeutics Alternatives Zai Lab Alternatives Vericel Alternatives Gemini Therapeutics Alternatives Kymera Therapeutics Alternatives Vera Therapeutics Alternatives Bausch Health Companies Alternatives Arrowhead Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNTH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts